Pumping the Brakes? Analysts Take on Apellis Pharmaceuticals, Inc. (:APLS)

When monitoring analyst ratings, investors can use the average brokerage recommendation score to determine the consensus view on the stock. The ABR is an average of the recommendations offered by research firms on a given equity. The ABR rank is displayed in the range of 1 to 5 where 1 indicates a Strong Buy and a rating of 5 represents a Strong Sell. While tracking shares of Apellis Pharmaceuticals, Inc. (:APLS), we have noted that the current average broker rating is currently 1.4. Going further, we can see that 4 Wall Street analysts have given the stock a Strong Buy or Buy rating, based on analysts polled by Zacks Research.

Stock analysis typically falls into two main categories. Some investors may prefer technical analysis, and others may prefer to study the fundamentals. Many investors will keep an eye on both. Technical analysis involves trying to project future stock price movements based on prior stock activity. Technicians strive to identify chart patterns and study other historical price and volume data. Technical investors look to identify trends when assessing a stock. The trend is typically considered to be the main direction of the share price. Trends are generally categorized as either up, down, or sideways. If a bullish trend is spotted, the trader may expect the upward trend to continue and thus try to capitalize on further upward action.   

Shifting gears, we can see that the current quarter EPS consensus estimate for Apellis Pharmaceuticals, Inc. (:APLS) is -0.82. This EPS estimate is using 2 sell-side analysts polled by Zacks Research. For the prior reporting period, the company posted a quarterly EPS of -0.87. As we move through earnings season, all eyes will be on the company to see if they can beat analyst estimates and show improvement from the last quarter. When a company reports actual earnings numbers, the surprise factor can cause a stock price to realize increased activity. Investors and analysts will be closely watching to see how the earnings results impact the stock after the next release. Many investors will decide to be cautious around earnings releases and delay buy/sell moves until after the stock price has steadied.

Viewing some popular support and resistance marks on shares of Apellis Pharmaceuticals, Inc. (:APLS), we can see that the 52-week high is presently $26.31, and the 52-week low is currently $11.47. When the stock is trading near the 52-week high or 52-week low, investors may be on the lookout for a potential break through the level. Looking at recent action, we can see that the stock has been trading near the $26.31 level. Investors may also want to track historical price activity. Over the past 12 weeks, the stock has changed 40.77%. Looking further back to the beginning of the calendar year, we note that shares have moved 99.47%. Over the previous 4 weeks, shares have seen a change of 22.83%. Over the last 5 trading sessions, the stock has moved 12.44%. Investors will be monitoring stock activity over the next few days to try and gauge which way the momentum is shifting.

At times, stock market volatility can wreak havoc on investors. When the market becomes highly volatile, investors may get the jitters and think they need to rush to action. In the heat of the moment, it can be tricky to see the clear skies in the distance. Investors may be best served at times to just let the cards fall where they may and not try to be a hero and drastically change the portfolio. Following a solid plan may allow investors to lay off the gas when times get tough. If the research is well done and the plan is in place, sticking to the plan might be the call. Of course nobody wants to see a significant drop in the value of stocks that they own. Being able to see the overall picture when the markets become turbulent may allow the investor to move forward with confidence.  

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*